Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Diagnosis and Treatment of Latent Tuberculosis Infection due to Initiation of Anti-TNF Therapy

  • Shim, Tae Sun (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2014.03.10
  • Accepted : 2014.03.24
  • Published : 2014.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Patients with immune-mediated inflammatory diseases (IMIDs) are increasingly being treated with anti-tumor necrosis factor (TNF) agents and are at increased risk of developing tuberculosis (TB). Therefore, diagnosis and treatment of latent TB infection (LTBI) is recommended in these patients due to the initiation of anti-TNF therapy. Traditionally, LTBI has been diagnosed on the basis of clinical factors and a tuberculin skin test. Recently, interferon-gamma releasing assays (IGRAs) that can detect TB infection have become available. Considering the high-risk of developing TB in patients on anti-TNF therapy, the use of both a tuberculin skin test and an IGRA should be considered to detect and treat LTBI in patients with IMIDs. The traditional LTBI treatment regimen consisted of isoniazid monotherapy for 9 months. However, shorter regimens such as 4 months of rifampicin or 3 months of isoniazid/rifampicin are increasingly being used to improve treatment completion rates. In this review, the screening methods for diagnosing latent and active TB before anti-TNF therapy in patients with IMIDs will be briefly described, as well as the current LTBI treatment regimens, the recommendations for managing TB that develops during anti-TNF therapy, the necessity of regular monitoring to detect new TB infection, and the re-initiation of anti-TNF therapy in patients who develop TB.

Keywords

References

  1. Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007;34:706-11.
  2. Brassard P, Lowe AM, Bernatsky S, Kezouh A, Suissa S. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 2009;61:300-4. https://doi.org/10.1002/art.24476
  3. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 2013;108:1268-76. https://doi.org/10.1038/ajg.2013.138
  4. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940-87. https://doi.org/10.1053/j.gastro.2006.01.048
  5. Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501-23. https://doi.org/10.1038/ajg.2009.727
  6. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72. https://doi.org/10.1002/art.21043
  7. Ke WM, Chen LS, Parng IM, Chen WW, On AW. Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan. Int J Tuberc Lung Dis 2013;17:1590-5. https://doi.org/10.5588/ijtld.13.0368
  8. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104. https://doi.org/10.1056/NEJMoa011110
  9. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, Cucho M, Alfaro J, Perich R, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005;64:1360-1. https://doi.org/10.1136/ard.2004.029041
  10. Ferrara G, Losi M, Meacci M, Meccugni B, Piro R, Roversi P, et al. Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2005;172:631-5. https://doi.org/10.1164/rccm.200502-196OC
  11. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-206. https://doi.org/10.1183/09031936.00028510
  12. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000;161(4 Pt 2):S221-47. https://doi.org/10.1164/ajrccm.161.supplement_3.ats600
  13. Chapman AL, Munkanta M, Wilkinson KA, Pathan AA, Ewer K, Ayles H, et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 2002;16:2285-93. https://doi.org/10.1097/00002030-200211220-00008
  14. Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004;2:309-13. https://doi.org/10.1016/S1542-3565(04)00060-6
  15. Schoepfer AM, Flogerzi B, Fallegger S, Schaffer T, Mueller S, Nicod L, et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 2008;103:2799-806. https://doi.org/10.1111/j.1572-0241.2008.02050.x
  16. Qumseya BJ, Ananthakrishnan AN, Skaros S, Bonner M, Issa M, Zadvornova Y, et al. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis 2011;17:77-83. https://doi.org/10.1002/ibd.21329
  17. Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. Seoul: Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention; 2011.
  18. National Institute for Health and Clinical Excellence. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: National Institute for Health and Clinical Excellence; 2011.
  19. Singanayagam A, Manalan K, Sridhar S, Molyneaux PL, Connell DW, George PM, et al. Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-alpha antagonist therapy. Thorax 2013;68:955-61. https://doi.org/10.1136/thoraxjnl-2013-203436
  20. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir Res 2006;7:56. https://doi.org/10.1186/1465-9921-7-56
  21. Metcalfe JZ, Cattamanchi A, McCulloch CE, Lew JD, Ha NP, Graviss EA. Test variability of the QuantiFERON-TB gold intube assay in clinical practice. Am J Respir Crit Care Med 2013;187:206-11. https://doi.org/10.1164/rccm.201203-0430OC
  22. Kobashi Y, Sugiu T, Mouri K, Obase Y, Miyashita N, Oka M. Indeterminate results of QuantiFERON TB-2G test performed in routine clinical practice. Eur Respir J 2009;33:812-5. https://doi.org/10.1183/09031936.00075008
  23. Igari H, Watanabe A, Sato T. Booster phenomenon of QuantiFERON- TB Gold after prior intradermal PPD injection. Int J Tuberc Lung Dis 2007;11:788-91.
  24. Vilaplana C, Ruiz-Manzano J, Gil O, Cuchillo F, Montane E, Singh M, et al. The tuberculin skin test increases the responses measured by T cell interferon-gamma release assays. Scand J Immunol 2008;67:610-7. https://doi.org/10.1111/j.1365-3083.2008.02103.x
  25. Choi JC, Shin JW, Kim JY, Park IW, Choi BW, Lee MK. The effect of previous tuberculin skin test on the follow-up examination of whole-blood interferon-gamma assay in the screening for latent tuberculosis infection. Chest 2008;133:1415-20. https://doi.org/10.1378/chest.07-2193
  26. van Zyl-Smit RN, Pai M, Peprah K, Meldau R, Kieck J, Juritz J, et al. Within-subject variability and boosting of T-cell interferon- gamma responses after tuberculin skin testing. Am J Respir Crit Care Med 2009;180:49-58. https://doi.org/10.1164/rccm.200811-1704OC
  27. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989;140:1189-93. https://doi.org/10.1164/ajrccm/140.5.1189
  28. Centers for Disease Control and Prevention (CDC); American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection: United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:735-9.
  29. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005;40:670-6. https://doi.org/10.1086/427802
  30. Yun JW, Lim SY, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. J Korean Med Sci 2007;22:779-83. https://doi.org/10.3346/jkms.2007.22.5.779
  31. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155-66. https://doi.org/10.1056/NEJMoa1104875
  32. Higuchi K, Harada N, Mori T. Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis. Respirology 2008;13:468-72. https://doi.org/10.1111/j.1440-1843.2008.01244.x
  33. Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008;27:19-30.
  34. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60: 800-5. https://doi.org/10.1136/thx.2005.046797
  35. Bermejo F, Algaba A, Chaparro M, Taxonera C, Garrido E, Garcia-Arata I, et al. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study. Dig Liver Dis 2013;45:733-7. https://doi.org/10.1016/j.dld.2013.03.005
  36. Kim KH, Lee SW, Chung WT, Kim BG, Woo KS, Han JY, et al. Serial interferon-gamma release assays for the diagnosis of latent tuberculosis infection in patients treated with immunosuppressive agents. Korean J Lab Med 2011;31:271-8. https://doi.org/10.3343/kjlm.2011.31.4.271
  37. Bourikas LA, Kourbeti IS, Koutsopoulos AV, Koutroubakis IE. Disseminated tuberculosis in a Crohn's disease patient on anti-TNF alpha therapy despite chemoprophylaxis. Gut 2008;57:425. https://doi.org/10.1136/gut.2007.132407
  38. Garcia Vidal C, Rodriguez Fernandez S, Martinez Lacasa J, Salavert M, Vidal R, Rodriguez Carballeira M, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005;40:756-9. https://doi.org/10.1086/427941
  39. Blackmore TK, Manning L, Taylor WJ, Wallis RS. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 2008;47:e83-5. https://doi.org/10.1086/588667
  40. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62. https://doi.org/10.1164/rccm.167.4.603
  41. Wallis RS, Kyambadde P, Johnson JL, Horter L, Kittle R, Pohle M, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004;18:257-64. https://doi.org/10.1097/00002030-200401230-00015
  42. Mayanja-Kizza H, Jones-Lopez E, Okwera A, Wallis RS, Ellner JJ, Mugerwa RD, et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J Infect Dis 2005;191:856-65. https://doi.org/10.1086/427995
  43. Centers for Disease Control and Prevention (CDC). Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep 2009;58:7-10.
  44. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5. https://doi.org/10.1086/383317
  45. Winthrop KL, Yamashita S, Beekmann SE, Polgreen PM; Infectious Diseases Society of America Emerging Infections Network. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 2008;46:1738-40. https://doi.org/10.1086/587989
  46. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416. https://doi.org/10.1164/rccm.200604-571ST
  47. Shim TS. Diagnosis and treatment of latent tuberculosis infection in patients with inflammatory bowel diseases due to initiation of anti-tumor necrosis factor therapy. Intest Res 2014;12:12-9. https://doi.org/10.5217/ir.2014.12.1.12

Cited by

  1. The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Blockers vol.30, pp.2, 2014, https://doi.org/10.3346/jkms.2015.30.2.173
  2. New Advances in Diagnosis of Latent Tuberculosis Infection: A Review Article vol.3, pp.1, 2014, https://doi.org/10.5812/pedinfect.22368
  3. Diagnosis and Treatment of Latent Tuberculosis Infection vol.78, pp.2, 2014, https://doi.org/10.4046/trd.2015.78.2.56
  4. Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus vol.264, pp.1, 2015, https://doi.org/10.1111/imr.12257
  5. QuantiFERON-TB Gold In-Tube Assay for Screening Arthritis Patients for Latent Tuberculosis Infection before Starting Anti-Tumor Necrosis Factor Treatment vol.10, pp.3, 2015, https://doi.org/10.1371/journal.pone.0119260
  6. Mycobacteria and autoimmunity vol.24, pp.4, 2015, https://doi.org/10.1177/0961203314559634
  7. Association between TNF -308G/A polymorphism and susceptibility to pulmonary tuberculosis in the Lur population of Iran vol.6, pp.1, 2014, https://doi.org/10.1016/j.apjtb.2015.09.017
  8. Clinical Applications of Interferon-gamma Release Assays vol.6, pp.1, 2014, https://doi.org/10.3343/lmo.2016.6.1.8
  9. How Should We Manage Latent Tuberculosis Infection in Patients Receiving Anti-TNF-α Drugs: Literature Review vol.18, pp.12, 2014, https://doi.org/10.5812/ircmj.27756
  10. Mycobacterium tuberculosis : An Adaptable Pathogen Associated With Multiple Human Diseases vol.8, pp.None, 2014, https://doi.org/10.3389/fcimb.2018.00158
  11. Tuberculosis in the era of anti-TNF-alpha therapy: Why does the risk still exist? vol.38, pp.1, 2014, https://doi.org/10.7705/biomedica.v38i0.3458
  12. Diagnosis and treatment of latent tuberculosis infection in patients undergoing treatment with immunobiologic agents: a four-year experience in an endemic area vol.45, pp.6, 2019, https://doi.org/10.1590/1806-3713/e20180225
  13. Frequency of Positive Conversion of Interferon-Gamma Release Assay Results Among Patients With Inflammatory Bowel Disease Treated With Non-tumor Necrosis Factor Inhibitors vol.8, pp.None, 2021, https://doi.org/10.3389/fmed.2021.670242
  14. Risk of Tuberculosis Development in Patients with Rheumatoid Arthritis Receiving Targeted Therapy: a Prospective Single Center Cohort Study vol.36, pp.10, 2021, https://doi.org/10.3346/jkms.2021.36.e70